Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ribitol - ML Bio Solutions

Next Previous
X
Search
Drug Profile

Ribitol - ML Bio Solutions

Alternative Names: Adonitol; BBP 418

Latest Information Update: 07 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atrium Health
  • Developer ML Bio Solutions
  • Class Small molecules; Sugar alcohols
  • Mechanism of Action Glycosylation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Limb girdle muscular dystrophies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Limb girdle muscular dystrophies

Most Recent Events

  • 01 Aug 2024 BridgeBio completes Type C meeting with the US FDA for Limb-girdle muscular dystrophies
  • 18 Jun 2024 The US FDA has grants Rare Pediatric Disease Designation (RPDD) for BBP 418 in the treatment of Limb-girdle Muscular Dystrophy Type 2I/R9
  • 31 Dec 2023 BridgeBio Pharma has multiple patents pending for methods of treatment, dosing methods, and compositions relating to ribitol in USA, Australia, Canada, Europe, China, Japan, and Mexico (SEC file 2023 - BridgeBio Pharma)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top